The FDA's approval is grounded in an evidence totality and comprehensive data package, which includes outcomes from a study.

SAN FRANCISCO -- More adults with moderate-to-severe Crohn's disease (CD) reached clinical remission after 6 months on ...

Celltrions Vegzelma becomes Europes top prescribed anticancer drug in two years Celltrions cancer treatment Vegzelma achieves impressive market dominance in Europe within two years ...

Celltrion launches ADC cancer drug trials in U.S. while planning additional INDs Celltrion accelerates its global drug ...

The US Food and Drug Administration (FDA) has approved Avtozma (CT-P47, tocilizumab-anoh) in both an intravenous (IV) and ...

CHMP Adopts Positive Opinion for Aflibercept, Pegfilgrastim Biosimilars:  On January 30, 2025, the European Medicines Agency (EMA) Committee ...

The biosimilar will be available in both subcutaneous and intravenous formulations and has nearly all the same indications as ...

The two products, both manufactured by Amgen, are aflibercept biosimilars Pavblu and Skojoy. Both biosimilars are indicated ...

NYU Langone Health in New York City reportedly cancelled the appointments of two transgender children scheduled to receive ...

The new biosimilar, Celltrion’s Avtozma, was approved in both IV and subcutaneous forms to treat inflammatory conditions such as arthritis.

Stocks rose more than 1 percent Thursday driven by tech giant gains with the Trump administration's sweeping tariffs on pause ...

SEOUL, Feb. 7 (Yonhap) -- Seoul shares fell marginally late Friday morning as investors took profit following three consecutive sessions of gains this week. The benchmark Korea Composite Stock Price ...